Technical Analysis for INBX - Inhibrx, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | N/A | N/A | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Hot IPO Pullback | Bullish Swing Setup | 0.78% | |
Down 3 Days in a Row | Weakness | 0.78% | |
Hot IPO Pullback | Bullish Swing Setup | -3.08% | |
NR7 | Range Contraction | -3.08% | |
NR7-2 | Range Contraction | -3.08% | |
NR7 | Range Contraction | -6.10% |
Alert | Time |
---|---|
Down 2 % | 1 day ago |
Fell Below Previous Day's Low | 1 day ago |
Down 1% | 1 day ago |
60 Minute Opening Range Breakdown | 1 day ago |
Up 3% | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/05/2024
Inhibrx, Inc. Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Solid Tumors Tumor Clinical Research Clinical Trial Sarcoma Antitrypsin Deficiency Fusion Protein Pseudomonas Clusters Of Differentiation Pseudomonas Aeruginosa
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 18.95 |
52 Week Low | 12.95 |
Average Volume | 383,675 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 0.00 |
20-Day Moving Average | 15.77 |
10-Day Moving Average | 14.75 |
Average True Range | 1.07 |
RSI (14) | 30.07 |
ADX | 0.0 |
+DI | 27.71 |
-DI | 21.43 |
Chandelier Exit (Long, 3 ATRs) | 15.75 |
Chandelier Exit (Short, 3 ATRs) | 16.15 |
Upper Bollinger Bands | 18.05 |
Lower Bollinger Band | 13.48 |
Percent B (%b) | 0.15 |
BandWidth | 28.93 |
MACD Line | -0.70 |
MACD Signal Line | -0.46 |
MACD Histogram | -0.2384 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 15.72 | ||||
Resistance 3 (R3) | 15.75 | 15.26 | 15.46 | ||
Resistance 2 (R2) | 15.26 | 14.87 | 15.25 | 15.37 | |
Resistance 1 (R1) | 14.72 | 14.63 | 14.99 | 14.69 | 15.29 |
Pivot Point | 14.23 | 14.23 | 14.37 | 14.22 | 14.23 |
Support 1 (S1) | 13.69 | 13.84 | 13.96 | 13.66 | 13.05 |
Support 2 (S2) | 13.20 | 13.60 | 13.19 | 12.97 | |
Support 3 (S3) | 12.66 | 13.20 | 12.88 | ||
Support 4 (S4) | 12.63 |